March 30, 2022 09:33 AM EDTUpdated March 31, 08:26 AM

Covid-19 roundup: CureVac, GSK debut second shot at pandemic vaccine; BioNTech expands Covid-19 trial

Kyle LaHucik

Senior Reporter

CureVac flamed out on its first attempt at producing a successful Covid-19 vaccine last June and the German biotech chalked up a second-gen approach …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: CureVac, GSK debut second shot at pandemic vaccine; BioNTech expands Covid-19 trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Exclusive: Florida cancer biotech raises $100M Series A

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Covid-19 roundup: Cure­Vac, GSK de­but sec­ond shot at pan­dem­ic vac­cine; BioN­Tech ex­pands Covid-19 tri­al

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Covid-19 roundup: CureVac, GSK debut second shot at pandemic vaccine; BioNTech expands Covid-19 trial

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Exclusive: Florida cancer biotech raises $100M Series A

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine